Abstract: Isolated polypeptides are disclosed herein, the isolated polypeptides comprising at least 90% identity to any one of: SEQ ID NO:1; SEQ ID NO:2; or SEQ ID NO:3, wherein the isolated polypeptide inhibits an interaction between palmitoyl acyl transferase zinc-finger DHHC type containing 17 (z D17) and c-jun N-terminal kinase (JNK). The polypeptides may be conjugated to a delivery and targeting moiety, such as the cell-membrane transduction domain of the HIV-1 Tat protein. There are also provided methods for treating a disease associated with cytotoxicity or excitotoxicity.
Abstract: The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
September 27, 2016
Assignee:
CSL BEHRING GMBH
Inventors:
Christoph Kleinschnitz, Marc Nolte, Guido Stoll, Gerhard Dickneite, Stefan Schulte, Bernhard Nieswandt, Ingo Pragst
Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys (SEQ ID NO: 17) or Thr-Phe-Leu-Lys-Cys (SEQ ID NO: 1), useful as a CCR2 non-competitive antagonist peptide.
Type:
Grant
Filed:
June 26, 2012
Date of Patent:
September 6, 2016
Assignee:
Universite Pierre Et Marie Curie (Paris 6)
Abstract: Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinson's Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.
Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
June 28, 2016
Assignees:
The Regents of the University of California, J. David Gladsone Institutes
Inventors:
Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
Abstract: The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720.
Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
June 14, 2016
Assignee:
biOasis Technologies, Inc.
Inventors:
Timothy Z. Vitalis, Reinhard Gabathuler
Abstract: This invention discloses the uses of IL-22 in the treatment and prevention of a nerve damage disease or a neurodegenerative disease. In particular, the invention discloses the uses of IL-22 or IL-22 dimers as follows: (i) can protect neurons to recover the functions of injured neurons after ischemic nerve damage in animals in vivo, thus enabling effective treatment of nerve damage diseases, (ii) can significantly inhibit the loss of dopaminergic neurons in substantia nigra in PD model animal, enhance the functions of dopaminergic neurons, significantly reduce neuronal apoptosis in hippocampus, improve learning and memory capacity of AD model rats, and effectively prevent neuronal loss, thereby enabling more effective treatment of neurodegenerative diseases.
Abstract: The present invention is based on applicants' discovery, disclosed herein, of agonists for the TAS2R receptors TAS2R1, TAS2R4, TAS2R9, TAS2R13, TAS2R14, TAS2R16, TAS2R44, TAS2R46, and TAS2R60. The assignment of agonists to these receptors makes assays for identifying compounds that modulate bitter taste possible. For example, the present invention provides methods of identifying compounds that inhibit the bitter taste due to these agonists. The present invention also provides methods of identifying compounds that selectively inhibit the bitter taste due to these agonists. The present invention further provides methods of identifying compounds that mimic the bitter taste due these agonists. The present invention also provides methods of identifying compounds that enhance the bitter taste due to these agonists.
Type:
Grant
Filed:
October 22, 2012
Date of Patent:
May 24, 2016
Assignees:
Chromocell Corporation, Kraft Foods Group Brands LLC
Inventors:
Kambiz Shekdar, Purvi Manoj Shah, Joseph Gunnet, Jane V. Leland, Peter H. Brown, Louise Slade
Abstract: The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.
Type:
Grant
Filed:
May 28, 2013
Date of Patent:
May 24, 2016
Assignees:
The Regents of the University of California, The United States of America as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Charles S. Zuker, Jayaram Chandrashekar, Greg Nelson, Yifeng Zhang, Nicholas J. P. Ryba, Mark A. Hoon
Abstract: Provided herein are compositions comprising light-activated chimeric proteins expressed on plasma membranes and methods of using the same to selectively depolarize excitatory or inhibitory neurons.
Type:
Grant
Filed:
September 23, 2015
Date of Patent:
May 17, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Karl Deisseroth, Ofer Yizhar, Lief Fenno, Peter Hegemann, Matthias Prigge
Abstract: A sweet taste substance or a sweet taste-regulating substance is detected by contacting a test substance with a cell that expresses a chimeric protein of human T1R2 and mouse T1R2, and/or a chimeric protein of human T1R3 and mouse T1R3, and may further express a G protein ? subunit, and by detecting an interaction between the chimeric proteins and the test substance.
Abstract: A family of novel feline bitter taste receptors, referred to as feline TAS2R (fTAS2R), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline bitter taste receptors and modulate their activity are disclosed.
Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
Type:
Grant
Filed:
May 15, 2014
Date of Patent:
April 5, 2016
Assignee:
Duke University
Inventors:
Daniel T. Laskowitz, Hana Dawson, Brad Kolls
Abstract: The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based therapeutics, such as polynucleotides, oligonucleotides and peptide nucleic acids. A CPPs of the invention provides a balance between good cell entry efficiency and low toxicity and comprises three contiguous domains: the central one being hydrophobic and the flanking ones consisting of arginine and aminohexanoic acid or beta-alanine residues. The hydrophobic domain contains a sequence selected from YQFLI, YRFLI, IQFLI and IRFLI.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
April 5, 2016
Assignee:
Medical Research Council
Inventors:
Michael John Gait, Andrey Alexandrovich Arzumanov, Amer F. Saleh, Matthew J. A. Wood, Corinne Betts, Taeyoung Koo
Abstract: Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein. Also disclosed are methods of producing a TATk-CDKL5 fusion protein from vectors containing a TATk-CDKL5 cDNA and methods of transducing cells with the vectors containing a TATk-CDKL5 cDNA and the TATk-CDKL5 fusion protein.
Abstract: A light-sensitive G-protein coupled receptor includes a light sensitive extracellular domain and a heterologous intracellular domain capable of modulating an intracellular signaling pathway.